Axial Biotherapeutics nets $25M for clinical gut-brain axis studies into autism and Parkinson’s

green bacteria
Axial plans to advance its lead product, AB-2004, into a phase 1b/2a clinical trial in adolescents with autism by the end of March. (Gerd Altmann)

Axial Biotherapeutics has raised $25 million to fund its programs aimed at the gut microbiome, for the treatment of Parkinson’s disease and autism spectrum disorder.

Seventure Partners led the series B round, through its microbiome-focused fund Health for Life Capital, with support from Axial’s previous backers, including the Longwood Fund, Domain Associates, Heritage Medical Systems and a number of individual investors.

“Leveraging the gut-brain axis, we have made extensive progress in our translational research and are excited to progress our clinical programs in 2019,” said David Donabedian, Ph.D., co-founder and CEO of Axial, which was named a 2017 Fierce 15 company for its three-pronged approach to CNS disorders, including small molecule-, biologic- and bacteria-based therapies to modify the microbiome.

FierceBiotech Executive Breakfast

Getting Real: The Changing Tide on Real-World Evidence in Drug Development

Join FierceBiotech and a panel of industry experts for an executive breakfast at BIO. We will discuss the impacts of real-world evidence on drug development and address the important questions that companies are facing including where to find the right talent & technology and how to deploy it internally or with partners. Join us in Philadelphia on June 5th for this important discussion.

The company’s Parkinson’s disease program evaluates organisms and genes found to be overrepresented in the guts of affected patients and has identified a pathway that can induce both gastrointestinal and motor symptoms in a preclinical model.

RELATED: FierceBiotech's 2017 Fierce 15 | Axial Biotherapeutics

Axial transplanted the microbiome of Parkinson’s patients into mice and found that motor deficit symptoms and inflammation were more severe in some compared to others that had gut bacteria from healthy controls, according to co-founder Sarkis Mazmanian, Ph.D., a professor of microbiology at Caltech.

RELATED: Microbiome startup Axial gains DepoMed executive as new CMO

In autism, the company’s research has focused on reducing the brain’s exposure to microbial metabolites, in the hopes of improving core and noncore symptoms related to behavior, as well as gut health. Axial plans to advance its lead product, AB-2004, into a phase 1b/2a clinical trial in adolescents with autism by the end of March.

Suggested Articles

Yale researchers discovered that AstraZeneca’s anti-VEGF cancer drug cediranib may boost the effectiveness of PARP inhibitors.

The FBI has launched its own probe into some of the world’s largest medtech companies, stemming from a Brazilian corruption case, Reuters reports.

AbbVie became yet another biopharma learning that aggressive brain cancer glioblastoma is one of the toughest cancers out there.